Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is on a mission to bring jobs back to the United States while commercializing stored energy solutions that meet the stringent quality standards necessary to power state-of-the-art technologies in a variety of expansive and growing industries. The company’s innovative ‘Made in the USA’ product line already includes multiple lithium-ion chemistries, technologies and form factors that are optimized to address four high-demand target markets – including motive applications, such as electric and hybrid electric fleet vehicles; stationary living space power for domestic, commercial and grid applications; remote control and portable devices; and starter motor batteries for motorcycles, jet skis, snowmobiles, boats, cars and trucks. Through these offerings, Oakridge targets major applications in the military, aerospace, marine, medical and telecom sectors, among others.

Under the guidance of an experienced management team, Oakridge is strategically positioned to achieve tremendous growth in the months to come. In January, the company announced the sale of its interest in Leclanché S.A., attaining the funds needed to satisfy a long-standing loan from Expedia Holdings Limited and entering 2016 completely debt-free and funded for growth. Shortly after this transaction, Oakridge entered into the full scale production phase of its corporate restructuring efforts, kick starting solid revenues that are expected to grow rapidly throughout the first quarter of 2016 and beyond.

“We are now well on our way to becoming a major player in the world lithium-ion battery manufacturing space,” Steve Barber, executive chairman and chief executive officer of Oakridge, stated in a January news release. “The addition of this significant capital into Oakridge provides the liquidity that we needed to launch this company from small scale production to one of the largest lithium battery manufacturing facilities in the world.”

As the company continues to exceed target goals for hiring of employees, acquisition of capital equipment for factory automation and introduction of informative tools designed to increase shareholder engagement and overall brand awareness, Oakridge is aggressively serving its target markets and engaging with the global lithium battery market. Look for Oakridge to continue benefitting from the expanded capacity offered by its new 69,000-square-foot facility in Melbourne, Florida, as it intensifies efforts to increase market share and roll out exciting new product lines moving forward.

For more information, visit www.oakridgeglobalenergy.com

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

Back in 2001, Ms. Gay, a frail 85-year-old, was out walking her dog, Blue, in Florida. She slipped and, falling to the ground, couldn’t get up. It wasn’t long before her plight was noticed by a ‘gator. Alligators in Florida typically measure over eight feet and weigh about 800 lbs. The only thing standing between her and certain death was her little Australian Blue Heeler, weighing in at 24 inches and 50 lbs, which took up a position in the line of the advancing predator. Ms. Gay watched the encounter with terrified, unbelieving eyes as the dog dodged, again and again, the giant jaws that snapped shut as the ‘gator attacked and advanced. Blue continued his rearguard action as he retreated until, spying a breach in the enemy’s defense, he sprang in and ripped one of its eyes out. The reptile turned and fled.

Such remarkable valor and loyalty can only come from a well-developed intelligence and emotional capacity. Dogs are very intuitive and appear to be particularly able to sense our emotional state. Some possess an innate ability to detect the onset of an epileptic seizure, hours before symptoms are experienced. With their keen sense of smell, they can ascertain subtle chemical changes in perspiration that signal distress or malfunction. Diabetes alert dogs can assist sufferers of hypoglycemia, which affects mostly people with type 1 diabetes, because they sense when their owner’s blood sugar is dropping rapidly or is dangerously low. But having a mind has a downside, too. Just like us, cats and dogs can become bored. Just like us, they require mental stimulation. When the Roman poet, Juvenal, prayed for a healthy mind in a healthy body (mens sana in corpore sano), his entreaty might have been for our feline and canine friends as well.

OurPet’s Company (OTCQX: OPCO) has been demonstrating its progressive attitude toward pets by recognizing their mental facets. Its approach has always been based on thoughtful analysis, not only of their physical well-being and safety, but their cognitive expression and emotional equilibrium. For example, it has developed a large (4-inch) IQ Treat Ball® that can be adjusted to suit a dog’s learning grade. The Treat Ball is filled with goodies which can only be obtained if the canine is able to discover the way in. To do so, it must uncover the hatches and apertures on the surface of the ball. It’s motivated to do so by the smell of the treats and their sound as it moves the ball around. Built on the same concept but simpler is the Buster Food Cube. The Buster Food Cube is filled with treats, and a dog must turn it in a way that allows the treats to slip through a small circular hole on one side of the cube. Innovative products like these for dogs, and cats, constitute about 50 percent of OurPet’s Company’s revenues, which were $22.8 million in 2014. 2015 revenues are expected to be reported within the next few weeks.

A press release (http://dtn.fm/Vb98R) announcing the latest market study by the American Pet Products Association (APPA), the 2015–2016 National Pet Owners Survey, estimates that the average amount spent annually on toys for dogs is $47. The survey also reports that there are some 77.8 million pet dogs in the U.S. Putting these two numbers together suggests that the market for dog toys has the potential to reach $3.7 billion if every household with a dog spends the average. A similar computation for feline toys puts the market potential at around $2.4 billion. The APPA study estimated a U.S. pet cat population of 85.8 million and the average annual per cat expenditure at $28.

These are markets that OurPet’s Company is just beginning to scratch. It is marketing its wide variety of premium, innovative, quality toys and accessories specially designed to awaken pets’ natural instincts under the OurPets brand. There’s tremendous room for growth and OurPet’s Company is in gear to increase market share. The company has been growing at an annually compounded rate of over 6%, twice the industry rate. OurPet’s Company’s strategic business plan calls for annual year-over-year sales growth of 15%-20% with targeted net income as a percentage of sales in the 10%-12% range. OurPet’s Company, with its innovative energy, is beginning to look like the Apple (NASDAQ: AAPL) of the pet toy industry.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

A pioneer in developing digital commerce technologies, Alternet Systems, Inc. (OTCQB: ALYI) aims to transform the electronic payment infrastructure that is so popular today. The company sees a bright future of global access to efficient and affordable banking and payment services. To align itself with this ever-increasing trend, Alternet Systems continues to develop advanced predictive data analytics applications for the mass consumer, telecommunications, and financial sectors, which have high growth markets. These applications include cutting-edge payment and financial solutions.

According to Andrew Mann, customer data director at the Co-Operative Group speaking at the Big Data and Analytics Retail Conference in London, successful companies know the power of data and use it to create a better experience for customers. It’s important to develop integrated customer solutions from data-driven analytics technology to make better business decisions.

Fortunately, Alternet Systems has a powerful Data Analytics Division to provide clients with customer trends and marketing solutions. Henryk Dabrowski, the company’s CEO, predicts that this division will “ramp up” last year’s established preliminary revenue base in its digital commerce operations. The Data Analytics Division is currently developing cloud-based solutions that offer micro segmentation and predictive analytics for clients. These solutions include translatable audience insight into market opportunities, channel optimization through micro segmentation analysis that gives the opportunity for store, web, and mobile locations, and a Connected Experience which offers purchasing power. These analytic solutions allow clients to quickly understand data in order to orchestrate new activities across multiple functional areas such as web and e-market personalization, loyalty incentives, KPI, and more.

Data Analytics is one of the fastest growing business sectors today. In 2015 alone, Data Analytics had a market value of $125 billion. By continuously advancing its Data Analytics Division, Alternet intends to lead the digital commerce industry while creating accessible solutions for everyone.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

The recent announcement by Avant Diagnostics, Inc (OTCQB: AVDX) and Amarantus Bioscience Holdings, Inc (OTCQX: AMBS) of their intention to tie the knot is a message of cheer for women who may be at risk for ovarian cancer. It also promises a partnership that will aggressively pursue opportunities in the rapidly expanding molecular diagnostics (MDx) market. A summary (http://dtn.fm/w2IbO) of a report from industry consultants Grand View Research estimates global molecular diagnostics market size at over $4.8 billion in 2014 with the U.S. market accounting for over $2.0 billion of that, and, according to a story (http://dtn.fm/D86pl) in The Journal of Precision Medicine, Grand View Research predicts the market will grow ‘at a compound annual growth rate (CAGR) of 8.7 percent to hit $8.02 billion by 2020, up from $4.47 billion in 2013. The growth will largely be driven by the rapidly increasing focus on theranostics and precision medicine, as well as the continuing development of advanced cancer diagnostic technologies like next-generation sequencing.’ Theranostics and precision medicine describe therapies with an individualized approach.

A press release (http://dtn.fm/AfG4c) on the Amarantus website proclaimed the purpose of the proposed merger was to ‘assist Avant Diagnostics in bolstering its product development and commercialization resources to accelerate the monetization of the combined company’s product pipeline… by harnessing the power of biomarkers based in the immune system.’ So what is molecular diagnostic testing, and how does it go about harnessing the power of biomarkers?

Molecular diagnostic testing has become possible since the successful mapping of the genes of humans. Spanning a period of over a decade, the Human Genome Project (HGP), initiated in 1990, was an international research effort to sequence and map all of the genes – together known as the genome – of members of our species, Homo sapiens. Completed in April 2003, the HGP gave us the ability, for the first time, to read nature’s complete genetic blueprint for building a human being. Now armed with that knowledge, it is possible to be able to detect specific sequences in deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) that may be associated with disease.

Employing these insights, Avant Diagnostics’ OvaDx is the first large panel biomarker monitoring test for ovarian cancer. It measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may signal an abnormal process or a disease. A biomarker, also called a molecular marker or a signature molecule, may also be used to see how well the body responds to a treatment for a disease or condition.

The molecular diagnostics space has seen a lot of activity in recent times. A story (http://dtn.fm/npFh5) in GEN states that many startup MDx companies, especially the ones engaged in cancer detection, have been snapped up by the big boys. Roche (OTCQX: RHHBY) has been particularly spendthrifty. Last year, it acquired a majority stake in Foundation Medicine (NASDAQ: FMI) for $1.18 billion. The pharmaceutical giant also paid around $625 million for Ariosa Diagnostics, another $450 million for Iquum, $350 million for Genia Technologies and an undisclosed sum for Signature Diagnostics.

Roche wasn’t the only large player to jump into the fray. In 2014, Veracyte (NASDAQ: VCYT) purchased Allegro Diagnostics for $21 million; Myriad Genetics (NASDAQ: MYGN) bought Crescendo Bioscience for $245 million; bioMérieux (OTC: BMXMF) bought BioFire Diagnostics for $486 million and Rosetta Genomics (NASDAQ: ROSG) purchased PersonalizeDx for $2 million in cash plus stock. Large companies like Roche, Qiagen (NASDAQ: QGEN), Becton Dickinson (NYSE: BDX) and Abbott (NYSE: ABT) have recognized the potential of the MDx market. They’re looking for companies like Avant and Amarantus to unlock value. Soon, it may be time to put out the welcome mat.

For more information, visit the company website at www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

Before the opening bell, Nutra Pharma Corporation (OTCQB: NPHC) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Nutra Pharma will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.

To view a complete list of presenting companies, visit http://steconference.com/presenting-companies

This announcement caps off what has been an eventful week for Nutra Pharma. On Tuesday, the biotechnology company announced the first of several growth steps expected to expand its core business strength, as well as its reach into important commercial markets. As part of this strategy, Nutra Pharma added Thomas W. Northrop, a member of New York-based management advisory and investment firm Tri-State Capital Partners, LLC, to its expanded management team. Northrop will serve as the company’s senior commercial development officer moving forward. From this position, he is expected to lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as the completion of scientifically rigorous pain relief trials in multiple settings.

“The addition of Tom Northrop and TriState’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deutsch, chief executive officer of Nutra Pharma, stated in Tuesday’s news release. “With Tri-State’s support, we now have the tools and a depth of resources that will allow for expansion into multiple markets, as well as to help accelerate the development and deployment of our prescription drug candidates.”

Additional information regarding Nutra Pharma’s 2016 growth plans is expected to be announced in the coming weeks. With opioid abuse at record levels and heightened recognition of the potential dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID), such as ibuprofen, the company will look to leverage its position in the biotechnology industry in order to capitalize on sizable global markets for innovative products addressing chronic pain.

Nutra Pharma operates as a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases – including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. The company also markets drug products for the treatment of chronic pain under the Nyloxin® and Pet Pain-Away brands.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

On Wednesday, leading independent equity research and corporate access firm SeeThruEquity announced that it has initiated coverage on Immune Therapeutics, Inc. (OTCQB: IMUN) with a 12-month price target of $0.61. IMUN is a specialty pharmaceutical company engaged in the manufacture, distribution and marketing of proprietary therapies targeting chronic, life-threatening diseases through the activation of the body’s immune system. The company’s technology platform includes two unique immunotherapies – Methionine-Enkephalin (MENK) and Low Dose Naltrexone (LDN), which is marketed as Lodonal™. MENK is a revolutionary option of therapy for those diagnosed with various forms of cancer, while LDN, which was originally developed as a treatment for individuals with opiate and alcohol dependence, now has the potential to become a primary drug used to treat a variety of autoimmune disorders, cancers and HIV/AIDS.

To view the full SeeThruEquity report, visit http://dtn.fm/q0yOP

Key highlights from the SeeThruEquity report include an update on IMUN’s progress toward marketing LDN in a large and relatively untouched market, results from the company’s phase I and II clinical trials studying MENK as an innovative solution to the treatment of various forms of cancer, successful enrollment and completion of clinical trials studying Lodonal in Nigeria and the potential impact of IMUN’s recently completed agreement with KRS Global for the further development and future profitability of the company.

“Immune Therapeutics, Inc. products and therapies are designed to exploit the intrinsic power of the immune system to help improve treatment of cancer, HIV/Aids, chronic inflammatory diseases, and autoimmune diseases,” Ajay Tandon, chief executive officer of SeeThruEquity, stated in yesterday’s news release.

SeeThruEquity’s coverage builds on what has been an exciting start to 2016 for IMUN shareholders. Last month, the company, alongside its partner organizations, achieved a major milestone in the development of Lodonal when it announced completion of its 90-day bridging trial comprised of HIV-positive patients. Following completion, IMUN submitted data to Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) in connection with the anticipated approval of Lodonal as an immune booster to improve the health and wellbeing of those affected by HIV-positive status and others with similarly compromised immune systems.

“September’s bridging trial enrollment completion and the efficiency of ensuing trials facilitated our submission of the results supporting the NAFDAC New Drug Application for Lodonal™,” Noreen Griffin, chief executive officer of IMUN, stated in a January news release. “It’s the objective of IMUN… to advance science and drug development with the intention of positively impacting patients with serious unmet healthcare needs.”

For more information, visit www.immunetherapeutics.com

According to the American Pet Products Association’s 2015-2016 National Survey (http://dtn.fm/0hCVP), there are roughly 86 million pet cats in the United States, up from about 21.5 million in 1970. Across the nearly 43 million American households that currently own a pet cat, one seemingly nondescript product has become virtually ubiquitous – cat litter. Cat litter originally burst onto the scene nearly 70 years ago, according to a report (http://dtn.fm/h8mJR) by The Washington Post, when a man named Ed Lowe repurposed some excess clay into a cleaner alternative to soil or sand, the standard solutions to feline waste in those days. This clay-based product, which he marketed as Kitty Litter, proved an exceptional choice for absorbing large quantities of waste while simultaneously controlling odors by encapsulating the cat waste. The total U.S. litter market is estimated to be about $2.5 billion with clay litters growing at approximately 3%, while the natural litter market is estimated to be about 10%-15% of the total and growing over 10% annually.

This clumping clay litter was a hit, quickly replacing sand as the standard in feline waste management. The clay clumps formed made waste removal easier and kept the odor physically locked up. Now having a cat in the home became easier, and less “smelly”, than ever before. Although the clay litter was a disrupter for the pet industry, there were some problems associated with it such as adding an estimated two million tons of non-biodegradable litter to the landfills, dust being inhaled by cats and possibly contributing to silicosis in the long run (also known as coal miners disease), a difficulty and inconvenience of transporting the heavy clay from the store to the home, and the realization that clay is a non-sustainable resource.

To try and combat the problems that came with using clay litter, cat owners started using biodegradable, natural litters made from grains such as wheat and corn. These “second generation” litters were sustainable, lighter, and had good odor control. Although these alternate litters were an improvement over clay, they had their limitations. They were more costly and more price variable since the grains were also used for food and fuel. These litters could have traces of fungicides, herbicides, and pesticides from their sources’ plant growth. Lastly, their high starch content could result in mold growth under certain conditions of warmth and moisture.

After years of extensive product development and testing, OurPet’s Company (OTCQX: OPCO) has ushered in the “third generation” of cat litter made from switchgrass and biochar, a non-food alternative to the other corn or wheat based natural cat litters in the marketplace. Switchgrass is a hardy, natural grass native to North America that does not require fertilization or the use of chemicals during plant growth, such as fungicides, herbicides, and pesticides and the toxins associated with them. Switchgrass is biodegradable and has a history of being used for flood control and ornamental purposes, not for feedstock or as a base for fuel. Biochar is made using the pyrolysis process to convert natural pine wood chips to activated, non-marking carbon particles that are highly odor and moisture absorbent. During pyrolysis, the volatile gases are collected and used as clean burning fuel while the CO2 is trapped in the pine wood with minimal CO2 release into the atmosphere.

The OurPet’s Switchgrass Biochar cat litter is biodegradable, all natural, sustainable, price competitive and price stable, 50% lighter than clay litter, and has excellent odor and moisture control with minimal dust and track-ability.

OurPet’s has filed a utility patent for their Switchgrass Biochar litter and plans on marketing it primarily under a private label strategy, with a branded option in certain specific situations. The Switchgrass Biochar litter will be launched at Global Pet Expo 2016, March 16-18. OurPet’s will be at booth #2455.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Short interest in OurPet’s Company (OTCQX: OPCO) has sharply fallen, presumably driven by a host of factors, including word that the specialty pet retailer has several new pet products and strategies on deck. The company’s total short interest was 1,900 shares in February, as reported by FDANewsAlert.com (citing FINRA), a drop of 70.7% from 6,500 shares previously reported. Based on average trading volume of 2,300 shares, the days-to-cover ratio is currently one day.

OPCO Tuesday said it will unveil a new product at next month’s Global Pet Expo, sending shares up nearly 11% to an intraday high of $0.89 on 1,000 traded hands. Earlier in February, the company announced its strategic partnership with Aplix IP Holdings Corp., a software and solutions provider in Japan that will help OPCO further develop its product lines in the $60 billion pet industry.

“We literally searched the world for the strategic partner who shares the same passion as we do and would closely work with us to bring these ideas to reality. We’re fortunate to have found what we were looking for in Aplix of Japan, a world leader in Bluetooth and Wi-Fi design, development and manufacture of related components,” OPCO CEO Dr. Steve Tsengas said in the news release. “OurPet’s and Aplix have invested extensive resources to develop new products fueled by smart technology and we look forward to collaborations that continue this development.”

Since July, shares of OPCO have risen nearly 13%, outperforming the S&P500 by 22.7%, most likely given a boost by well-paced and frequent updates on new products, a new communication strategy, executive appointment and strong second-quarter, third-quarter and nine-month 2015 performances.

OPCO currently has more than 160 issued or pending patents and derives more than 75% of its revenue from proprietary products. For the first nine months of 2015, OPCO reported revenues of $17.1 million, an increase of 6% compared to the comparable period of 2015. Gross profit increased 15% to $5.4 million vs. the year prior, while gross profit margin increased 2.5 percentage points to 31.6% for the first nine months of 2015 from 29.1% the prior year. Net income for the first nine months of 2015 increased 146% to $886,319, or $0.04 per share, from $359,935, or $0.02 per share, for the same period in 2014.

Increased market exposure and growing recognition of the company’s firming position in the specialty pet retail market have squeezed out the majority of short sellers looking to profit off a misplaced forecast for a decline in OPCO’s share price.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Parkinson’s disease is caused by death of dopamine-producing cells in a brain region called the substantia nigra, which hampers movement. Current treatments focus primarily on replacing the lost dopamine, but these treatments eventually fail because the dopamine-making cells continue to die. For this reason, stem cell therapy is of interest. International Stem Cell Corporation (OTCQB: ISCO) is a biotechnology company that focuses on the development of therapeutic and biomedical products worldwide. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. International Stem Cell Corp. develops cell types, including neural stem cells, for the treatment of Parkinson’s disease and other neurological disorders.

Parkinson’s disease is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the U.S. are living with Parkinson’s disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

The amount of money that the U.S. and individuals spend each year on Parkinson’s disease is staggering. The combined direct and indirect costs of Parkinson’s disease – including treatment, social security payments and lost income from inability to work – is estimated to be nearly $25 billion per year in the U.S. alone. Medication costs for an individual person with Parkinson’s average $2,500 a year, and therapeutic surgery can cost up to $100,000 per individual, according to the Parkinson’s Disease Foundation’s website (http://dtn.fm/4uIwr).

Stem cell research has the potential to significantly impact the development of disease-modifying treatments for Parkinson’s disease, and considerable progress has been made toward creating dopamine-producing cells from stem cells. The development of new cell models of Parkinson’s disease is a particularly promising area of stem cell research, as the current lack of progressive, predictive models of Parkinson’s disease remains a major barrier to drug development.

International Stem Cell Corp. has pioneered development of a new class of stem cells – human parthenogenetic stem cells (hpSCs) – that has the best characteristics of each of the other classes of stem cells. These stem cells are created by chemically stimulating the oocytes (eggs) to begin division. The oocytes are not fertilized and no viable embryo is created or destroyed. The ethical advantage of derivation from unfertilized oocytes, combined with immunomatching advantages, makes these stem cells a very promising source for cell-based therapy.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

GTX Corp. (OTC: GTXO) stands at the forefront of wearable GPS technology while being a leader in two-way personal location services. Headquartered in Los Angeles, the company shows off its knowledge of miniaturized and low-power consumption GPS, BLE, and cellular tracking solutions. GTXO has distributors in 13 countries that send-off customizable solutions like hardware, apps, and connectivity services to valued customers.

GTXO promises real-time location and monitoring solutions that are on call 24/7. These solutions are specially made to track people, pets, vehicles, and high-end assets. Through its many devices, customers can track and receive updates constantly via a data monitoring server that gives history and current movements using Google Maps. Customers can also set up geozones, which are specific areas that, if breached or encountered, will result in an instant notification.

The company’s award-winning GPS SmartSole still stands as its headliner, most recently appearing on FOX News in one of the network’s Tech Take segments. This tracking insole fits perfectly inside the shoe of a loved one who tends to wander. Using GTXO’s latest technology, wearers are able to be located in an instant through the company’s app or portal.

The Take Along Tracker is another device offered by GTXO. It is a miniature quad-band receptor the size of a D-battery. It’s light and thin, which means it can easily be placed on a person, pet, or object. This GPS/GSM communication device syncs with the GTX Corp. Tracking Portal to give instant notifications regarding geofences and locations. It also comes with a long battery life, SOS Button, and voice call capabilities.

Taking home multiple awards – including Second Place Winner of the CTIA E-Tech Awards in the Wearables, Health, Fitness, and Wellness category – GTXO aims to continue “empowering the global community” by consistently developing its innovative portfolio. The company believes in giving families a sense of connectedness and peace of mind through its technology.

For more information, visit www.gtxcorp.com

Let us hear your thoughts: GTX Corp. Message Board